Contact Us

Background

Clinical stage effective immunotherapy - benefit for all patient types

OVM is a clinical-stage biopharma developing advanced therapeutic cancer vaccines

The Old Road Campus healthcare research building at Oxford University
Image credit: Oxford University
Oxford Vacmedix UK (OVM) was established as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP).
These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical.

Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemotherapy and radiotherapy.
AdobeStock_906480988 Patient injection_sm
Providing High Quality Test Services For Your Health!

Redefining personalised medicine

Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemotherapy and radiotherapy.
The Oxford Vacmedix ROP technology has a unique dual mode of action which significantly enhances the immunogenicity of the vaccines and is applicable for all HLA types. This completely new proprietary approach to immunotherapy redefines the definition of personalised medicine. ROP vaccines promise effective treatment of cancer, making it easier to deliver and much more economical than existing personalised medicine.
Technology
banner-3

Recombinant Overlapping Peptides (ROP)

Developed at the Universities of Harvard and Oxford
banner-3

Focus on novel cancer therapeutics

To provide effective immunotherapy for all patients
banner-3

Patents: Strong proprietary position

Our patents cover the ROP technology until 2042
bg-section-04

Trust Towards OurnShared Purpose

We care for our patients, each other and our communities and excellence is the standard of working quality.
Read More
bg-section-04

Empowered To Change,nAct, And To Adapt

We work with you to develop individualised care plans, including manage of chronic diseases can provide referrals.
Read More
bg-section-04

New AdvancednInstruments

We can provide referrals or advice about the type of practitioner you require to treat all enquiries sensitively.
Read More
Something to say here....
University of Oxford logo
Department of Oncology
1200px-UKRI_IUK-Logo_Horiz-RGB
Something to say here....
Our Management Team
University of Oxford
Department of Oncology
1200px-UKRI_IUK-Logo_Horiz-RGB

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

University of Oxford
Department of Oncology
OVM UK, clinical trials - map

Company Timeline

Dec 24
OVM-200 Phase 1 clinical trial extended

Trial extended to include additional immunisations.

Nov 24
Opens Series B Investment

Announces Lead investment of $3 million in Oxford from existing investors. Prostate Cancer Research invests in Series B.

Jul 24
Innovate UK grant for OVM-200 clinical trial

Oct 23
OVM-200 Starts Phase 1b Clinical Trials

Mar 23
OVM-200 Completed Phase 1a Clinical Trials

The dose escalation and safety part of the clinical trial was completed with no serious adverse events (SAEs).

May 22
Innovate UK grant for development of novel T-cell potency assays

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays, supporting the future development of immunotherapy and vaccines.

Nov 21
OVM-200 Starts Phase 1a Clinical Trial

First patient treated in OVM-200 clinical trial. The Clinical Trial begins with the treatment of the first patient at the Sarah Cannon Research Institute in London.

Aug 21
OVM-200 Received MHRA Approval

MHRA approval of Phase 1 clinical trial of OVM-200. Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on ROP technology.

Mar 21
OVM-200 Completes Preclinical Studies

Dec 20
Completion of Good Manufacturing Practice batch

Mar 18
Completes Series A Investment

OVM starts pre-clinical development in earnest following Series A investment of $12.5m USD.

Sep 12
Established as a spinout from the University of Oxford

With an exclusive licence to develop ROP technology, developed by Professor Shisong Jiang, from the University of Oxford.

en_GBEnglish
en_GBEnglish